Janet Maynard News Today

The FDA is creating a new advisory committee related to potential treatments for genetic metabolic diseases. Genetic metabolic diseases are conditions that disrupt an individual's metabolism, which is the chemical process responsible for converting food into energy and eliminating toxins from the bo

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.

The FDA has approved Veozah (fezolinetant) for the treatment of moderate to severe vasomotor symptoms due to menopause.

/PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists...

/PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and...

Hot flashes occur during menopause – a normal stage of life women go through in their mid-to-late 40s. Lasting between 30 seconds and 10 minutes, these cause unpleasant sensations in the chest, arms, neck and face. Experts say they can be a serious physical burden on women and impact their quality of life

The FDA just approved Veozah to treat hot flashes in menopausal women. Here’s how it works, why it’s a game-changer for certain women, and what it costs.

By Brenda Goodman, CNN

The non-hormonal drug Veozah was approved by the FDA for treating hot flashes and night sweats caused by menopause.

The FDA has approved Veozah (fezolinetant) for the treatment of moderate to severe vasomotor symptoms due to menopause.